Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for
patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Relapse after stem cell transplantation for Philadelphia chromosome–positive (Ph+) acute
lymphoblastic leukemia (ALL) remains a significant challenge. In this systematic review, we …

Abstract Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
(ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell …

Background Trials of imatinib have provided evidence of activity in adults with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given …

This study aimed to determine the impact of tyrosine kinase inhibitors given pre-and post-
allogeneic stem cell transplantation on long-term outcome of patients allografted for …

Childhood BCR-ABL1–positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
has an unfavorable outcome and shows high frequency of IKZF1 deletions. The prognostic …

Epithelial-to-mesenchymal transition (EMT) has been closely linked with therapy resistance
and cancer stem cells (CSCs). However, EMT pathways have proven challenging to …

The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic …

Simple Summary Outcome of patients with Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) dramatically improved during the past 20 years with the …